A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

NCT07217171 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer
Squamous Cell Carcinoma of the Lung
Esophageal Squamous Cell Carcinoma
Tongue Squamous Cell Carcinoma
Cutaneous Squamous Cell Cancer
Penile Squamous Cell Carcinoma
Anal Squamous Cell Carcinoma
Vulvar Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
Vaginal Squamous Cell Carcinoma
Urethral Squamous Cell Carcinoma

Interventions

DRUG: EVOLVE104
DRUG: EVOLVE104

Sponsor

EvolveImmune United, Inc